Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | London | GBP | Real-time | |
3LAZ | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZN | NASDAQ | USD | Real-time | |
AZNCF | OTC Markets | USD | Delayed | |
AZNN | BIVA | MXN | Delayed | |
AZNN | Mexico | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZNPy | Frankfurt | EUR | Delayed | |
AZN | Frankfurt | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZN | Xetra | EUR | Delayed | |
AZN | Buenos Aires | ARS | Delayed | |
AZNA | Vienna | EUR | Real-time |
AstraZeneca PLC reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 1,428 million compared to USD 755 million a year ago. Revenue was USD 45,811 million compared to USD 44,351 million a year ago. Net income was USD 5,955 million compared to USD 3,288 million a year ago. Basic earnings per share from continuing operations was USD 3.84 compared to USD 2.12 a year ago. Diluted earnings per share from continuing operations was USD 3.81 compared to USD 2.11 a year ago.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 12024 | 11492 | 11416 | 10879 |
Gross Profit | 9729 | 9437 | 9499 | 9106 |
Operating Income | 2034 | 2533 | 2602 | 2687 |
Net Income | 960 | 1374 | 1818 | 1803 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 101119 | 96086 | 96543 | 96687 |
Total Liabilities | 61953 | 58865 | 59127 | 60876 |
Total Equity | 39166 | 37221 | 37416 | 35811 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 2380 | 3114 | 1718 | 3133 |
Cash From Investing Activities | -1077 | -1221 | -520 | -1246 |
Cash From Financing Activities | -291 | -2726 | -1519 | -2031 |
Net Change in Cash | 1018 | -852 | -357 | -155 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review